Intercept Pharmaceuticals v. Zenara Pharma: Obeticholic Acid Patent Dispute Ends in Consent Judgment
Was möchten Sie als Nächstes tun?
Wählen Sie Ihren Weg entsprechend Ihren aktuellen Bedürfnissen:
📋 Fallzusammenfassung
| Fallbezeichnung | Intercept Pharmaceuticals, Inc. v. Zenara Pharma Private Limited |
| Fallnummer | 1:22-cv-01215 (D. Del.) |
| Gericht | US-Bezirksgericht für den Bezirk Delaware |
| Dauer | Sep 2022 – Mar 2024 537 days |
| Ergebnis | Plaintiff Win — Consent Judgment & Permanent Injunction |
| Streitige Patente | |
| Beschuldigte Produkte | Obeticholic acid tablets (5 mg and 10 mg) |
Fallübersicht
Die Parteien
⚖️ Kläger
A biopharmaceutical company specializing in bile acid chemistry, with a substantial IP portfolio around obeticholic acid (OCA).
🛡️ Beklagter
An India-based generic pharmaceutical manufacturer seeking approval to market generic obeticholic acid tablets in 5 mg and 10 mg dosages.
Die streitigen Patente
This landmark case involved six U.S. patents spanning obeticholic acid composition, formulation, and method claims. These patents collectively form a layered exclusivity strategy — a common approach in Hatch-Waxman litigation where innovators stack various patent types to extend commercial protection.
- • US9238673B2 (App. No. 13/919734)
- • US10047117B2 (App. No. 14/947658)
- • US10052337B2 (App. No. 15/139138)
- • US10174073B2 (App. No. 15/496398)
- • US10751349B2 (App. No. 16/248512)
- • US10758549B2 (App. No. 16/787796)
Entwicklung eines Generikums?
Check if your formulation might infringe these or related pharmaceutical patents before filing your ANDA.
Das Urteil und die rechtliche Analyse
Ergebnis
On March 6, 2024, Judge Noreika entered a Consent Judgment and Permanent Injunction by stipulation of both parties. The judgment reflects a negotiated resolution codified in a private Settlement Agreement. Specific financial terms were not publicly disclosed. Zenara and its affiliates are permanently enjoined from making, using, selling, offering to sell, importing, or distributing the Zenara Products, except as specifically authorized by the Settlement Agreement. The FDA retains authority to grant final approval of ANDA No. 214855.
Wichtige rechtliche Fragen
This action arose as a classic Hatch-Waxman ANDA infringement dispute under 35 U.S.C. § 271(e)(2). Upon Zenara’s filing of ANDA No. 214855 with a Paragraph IV certification, Intercept exercised its statutory right to file suit within 45 days, triggering a 30-month stay of FDA approval. The settlement, structured as a consent judgment with injunctive relief, strongly suggests Intercept negotiated from a position of patent strength, preserving its commercial position against generic competition.
Freedom to Operate (FTO) Analysis for Pharmaceutical IP
Dieser Fall verdeutlicht die kritischen IP-Risiken in der pharmazeutischen Entwicklung. Wählen Sie Ihren nächsten Schritt:
📋 Die Auswirkungen dieses Falls verstehen
Informieren Sie sich über die spezifischen Risiken und Auswirkungen dieses Rechtsstreits.
- Alle zugehörigen Patente in diesem Technologiebereich anzeigen
- See which companies are most active in obeticholic acid IP
- Understand claim construction patterns for FXR agonists
🔍 Das Risiko meines Produkts überprüfen
Führen Sie eine umfassende FTO-Analyse für Ihre eigene pharmazeutische Formulierung durch.
- Input your drug substance or formulation details
- AI identifies potentially blocking patents & ANDA filings
- Erhalten Sie einen umsetzbaren Risikobewertungsbericht
Hochrisikogebiet
Obeticholic acid formulations & derivatives
6 geltend gemachte Patente
In obeticholic acid portfolio
Strategische FTO-Planung
Crucial for ANDA filers
✅ Wichtigste Erkenntnisse
Six-patent assertion strategies in Hatch-Waxman litigation create compounding negotiation leverage and increase the cost-risk calculus for generic challengers.
Verwandte Rechtsprechung suchen →Consent judgments with retained court jurisdiction provide durable, court-enforceable protection beyond private contract remedies.
Präzedenzfälle erkunden →Häufig gestellte Fragen
Six U.S. patents were asserted: US9238673B2, US10047117B2, US10052337B2, US10174073B2, US10751349B2, and US10758549B2 — all covering obeticholic acid compositions, formulations, or methods of use.
The parties reached a negotiated settlement agreement resolving all claims. The consent judgment codified agreed injunctive relief preventing Zenara from commercializing its ANDA-referenced obeticholic acid tablets without authorization.
The outcome reinforces that multi-patent Hatch-Waxman enforcement, combined with strategic Delaware venue selection, remains highly effective at securing negotiated market entry control — often without requiring a trial on the merits.
Sind Sie bereit, Ihre Patentstrategie zu stärken?
Schließen Sie sich den über 18.000 Fachleuten aus dem Bereich des geistigen Eigentums an, die PatSnap Eureka nutzen, um mit KI-gestützter Präzision Recherchen zum Stand der Technik durchzuführen, Patentanmeldungen zu erstellen und Wettbewerbslandschaften zu analysieren.
Referenzen
- PACER — Case No. 1:22-cv-01215, D. Del.
- USPTO Patent Full-Text Database — Intercept’s patent portfolio
- FDA Orange Book — Obeticholic acid listings
- Cornell Legal Information Institute — 35 U.S.C. § 271(e)(2)
- FTC v. Actavis, Inc. — Supreme Court Decision (2013)
Dieser Artikel dient ausschließlich zu Informationszwecken und stellt keine Rechtsberatung dar. Alle Angaben zu den Fällen stammen aus öffentlich zugänglichen Gerichtsakten. Informationen zu den Funktionen der Plattform finden Sie auf PatSnap.